Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical and rare disease company with approved and investigational therapies targeting rare liver and neurodevelopmental conditions. The Mirum news feed on Stock Titan aggregates company announcements, press releases and corporate disclosures so readers can follow how its commercial portfolio and pipeline evolve over time.
Investors and followers of MIRM can review news about LIVMARLI (maralixibat), CHOLBAM (cholic acid) and CTEXLI (chenodiol), including regulatory updates, commercial milestones and clinical study developments. Coverage also includes updates on clinical-stage programs such as volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV) in connection with the proposed Bluejay Therapeutics acquisition, and MRM-3379 for Fragile X syndrome (FXS).
News items commonly highlight Mirum’s participation in healthcare and investor conferences, private placement financings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and material events reported via Form 8-K filings. Company press releases also discuss regulatory designations, study initiations, enrollment updates and planned timelines for key clinical readouts, as described in Mirum’s own communications.
This page offers a centralized view of Mirum-related headlines, allowing readers to track commercial performance commentary, pipeline progress and transaction announcements in one place. For users researching MIRM stock or the company’s rare disease programs, the news feed provides direct access to the narrative Mirum shares with the market.
Mirum Pharmaceuticals (NASDAQ: MIRM) has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss both the financial performance and recent corporate developments.
Investors and interested parties can access the call through multiple channels:
- U.S./Toll-Free: +1 833 470 1428
- International: +1 404 975 4839
- Passcode: 549600
Additionally, a webcast will be available through the Events & Presentations section on Mirum's website. For those unable to attend live, a replay of the webcast will remain accessible for 30 days following the call.
Mirum Pharmaceuticals (NASDAQ: MIRM) has announced upcoming data presentations at three major medical congresses in May 2025: Digestive Disease Week (DDW) in San Diego, European Association for the Study of the Liver (EASL) in Amsterdam, and ESPGHAN in Helsinki.
A key highlight includes new 28-week data from the Phase 2b VANTAGE study of volixibat in PBC patients, showing significant improvements in cholestatic pruritus. The study demonstrated that 70% of volixibat-treated patients achieved ≥50% reduction in serum bile acid levels, with improvements in fatigue and sleep. The most common side effect was mild to moderate diarrhea.
The presentations will feature data from LIVMARLI and volixibat studies across multiple sessions, including oral presentations, posters, and symposiums focusing on cholestatic liver diseases, PFIC, and Alagille syndrome treatment outcomes.
Mirum Pharmaceuticals (NASDAQ: MIRM) has received FDA approval for a new tablet formulation of LIVMARLI® (maralixibat) for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).
The tablet version will complement the existing liquid formulation, offering greater flexibility in treatment options. While younger patients can continue using the liquid form, older patients will benefit from a convenient one-tablet per dose option. The company plans to make LIVMARLI tablets available in June through Mirum Access Plus.
Mirum Pharmaceuticals (MIRM) has announced inducement awards for seven new employees under its 2020 Inducement Plan. The awards, approved by the Compensation Committee, include:
- 39,740 non-qualified stock options with an exercise price of $39.12 per share (closing price on April 10, 2025)
- 19,830 restricted stock units (RSUs)
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both awards are contingent on continued employment with Mirum through vesting dates.
Mirum Pharmaceuticals (NASDAQ: MIRM) announced that its partner Takeda Pharmaceutical has received approval from the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® (maralixibat) oral solution. The approval is for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) in Japan.
LIVMARLI becomes the first and only treatment available for these conditions in Japan. Under the exclusive license agreement signed in September 2021, Mirum will receive a percentage of Takeda's annual net sales. The medication is currently approved for ALGS-related pruritus in over 40 countries and for PFIC in more than 30 countries worldwide.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement awards granted by its Compensation Committee on March 10, 2025, to five new employees. The awards include:
- Non-qualified stock options to purchase 17,620 shares at $43.01 per share (closing price on March 10, 2025)
- 9,290 restricted stock units (RSUs)
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both awards require continued employment with Mirum and were granted under the company's 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (NASDAQ: MIRM) reported strong financial results for Q4 and full-year 2024, with total net product sales reaching $336.4 million, up from $178.9 million in 2023. The company provided guidance for 2025, expecting global net product sales of $420-435 million.
LIVMARLI sales contributed $213.3 million in 2024, while Bile Acid Medicines generated $123.1 million. The global LIVMARLI business expanded to 30 countries, including successful launches in major European markets.
Key pipeline developments include expected completion of the VISTAS study enrollment for volixibat in PSC during H2 2025, with topline data in 2026. The company reported $292.8 million in cash and investments as of December 31, 2024, compared to $286.3 million at the end of 2023.
Mirum Pharmaceuticals (NASDAQ: MIRM) has received FDA approval for CTEXLI™ (chenodiol) tablets, becoming the first and only approved treatment for adults with cerebrotendinous xanthomatosis (CTX), a rare and progressive disease. The approval is based on the Phase 3 RESTORE study results, which demonstrated highly significant reduction in bile alcohols (p<0.0001) with a 20-fold difference between placebo and CTEXLI-treated patients.
The study showed CTEXLI improved both urine bile alcohol and serum cholestanol levels. In CTX patients, a deficiency of bile acid chenodeoxycholic acid leads to toxic accumulation of cholestanol, causing irreversible neurologic dysfunction. The drug has been granted FDA Orphan Drug exclusivity and will be available through Mirum Access Plus (MAP), the company's patient support program.
Mirum Pharmaceuticals (NASDAQ: MIRM) has scheduled its fourth quarter and year-end 2024 financial results announcement for Wednesday, February 26, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the financial results and recent corporate progress.
Investors can access the call via U.S./Toll-Free number +1 833 470 1428 or International number +1 404 975 4839 using passcode 126145. A webcast option is also available through the Events & Presentations section on Mirum's website, with a replay accessible for 30 days.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
